Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EWSR1::POU2AF3(COLCA2) Sarcoma: An Aggressive, Polyphenotypic Sarcoma With a Head and Neck Predilection.
Koshyk O, Dehner CA, van den Hout MFCM, Bempt IV, Sciot R, Huang HY, Agaimy A, Din NU, Klubíčková N, Mosaieby E, Skálová A, Michalová K, Schöffski P, Oliveira AM, Halling KC, Gupta S, Gross JM, Nin JWM, Michal M, Folpe AL, Kosemehmetoglu K, Torres-Mora J, Michal M. Koshyk O, et al. Among authors: schoffski p. Mod Pathol. 2023 Dec;36(12):100337. doi: 10.1016/j.modpat.2023.100337. Epub 2023 Sep 22. Mod Pathol. 2023. PMID: 37742928 Free article.
Extensive surgical resections for rare pleural neoplasms: a single-center experience with a yolk sac tumor and synovial sarcoma.
Vandaele T, Van Slambrouck J, Schöffski P, Dumez H, Weynand B, Sciot R, Barbarossa A, Provoost AL, Van de Voorde K, Debaveye Y, Bouneb S, Nafteux P, Ceulemans LJ. Vandaele T, et al. Among authors: schoffski p. World J Surg Oncol. 2024 Apr 16;22(1):96. doi: 10.1186/s12957-024-03367-9. World J Surg Oncol. 2024. PMID: 38622623 Free PMC article.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. Among authors: schoffski p. N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282897 Clinical Trial.
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
Schenker M, Burotto M, Richardet M, Ciuleanu TE, Gonçalves A, Steeghs N, Schoffski P, Ascierto PA, Maio M, Lugowska I, Lupinacci L, Leary A, Delord JP, Grasselli J, Tan DSP, Friedmann J, Vuky J, Tschaika M, Konduru S, Vemula SV, Slepetis R, Kollia G, Pacius M, Duong Q, Huang N, Doshi P, Baden J, Di Nicola M. Schenker M, et al. Among authors: schoffski p. J Immunother Cancer. 2024 Aug 6;12(8):e008872. doi: 10.1136/jitc-2024-008872. J Immunother Cancer. 2024. PMID: 39107131 Free PMC article. Clinical Trial.
Potentially actionable targets in synovial sarcoma: A tissue microarray study.
De Cock L, Paternostro F, Vanleeuw U, Wyns K, Laenen A, Lee CJ, Sciot R, Wozniak A, Schöffski P. De Cock L, et al. Among authors: schoffski p. Transl Oncol. 2024 Oct;48:102057. doi: 10.1016/j.tranon.2024.102057. Epub 2024 Jul 18. Transl Oncol. 2024. PMID: 39029378 Free PMC article.
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
Leboulleux S, Kapiteijn E, Litière S, Schöffski P, Godbert Y, Rodien P, Jarzab B, Salvatore D, Zanetta S, Capdevila J, Bastholt L, De La Fouchardiere C, Lalami Y, Bardet S, Cornélis F, Dedecjus M, Links T, Sents W, Schlumberger M, Locati DL, Newbold K. Leboulleux S, et al. Among authors: schoffski p. Front Endocrinol (Lausanne). 2024 Jun 27;15:1403687. doi: 10.3389/fendo.2024.1403687. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39015176 Free PMC article. Clinical Trial.
Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report.
Schöffski P, Jones RL, Agulnik M, Blay JY, Chalmers A, Italiano A, Pink D, Stacchiotti S, Valverde C, Vincenzi B, Wagner MJ, Maki R. Schöffski P, et al. ESMO Open. 2024 Jul;9(7):103487. doi: 10.1016/j.esmoop.2024.103487. Epub 2024 Jun 28. ESMO Open. 2024. PMID: 38943735 Free PMC article. Review.
Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours.
Zago Baltazar R, Claerhout S, Vander Borght S, Spans L, Sciot R, Schöffski P, Hompes D, Sinnaeve F, Wafa H, Renard M, van den Hout MF, Vernemmen A, Libbrecht L, De Roo AK, Mazzeo F, van Marcke C, Deraedt K, Bourgain C, Vanden Bempt I. Zago Baltazar R, et al. Among authors: schoffski p. J Pathol Clin Res. 2024 May;10(3):e12376. doi: 10.1002/2056-4538.12376. J Pathol Clin Res. 2024. PMID: 38738521 Free PMC article.
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.
Gantzer J, Toulmonde M, Severac F, Chamseddine AN, Charon-Barra C, Vinson C, Hervieu A, Bourgmayer A, Bertucci F, Ryckewaert T, Valentin T, Firmin N, Chaigneau L, Bompas E, Follana P, Rioux-Leclercq N, Soibinet-Oudot P, Bozec L, Le Loarer F, Weingertner N, Chevreau C, Duffaud F, Blay JY, Kurtz JE, Schöffski P, Brahmi M, Malouf GG. Gantzer J, et al. Among authors: schoffski p. Cancer. 2024 Jul 1;130(13):2304-2314. doi: 10.1002/cncr.35277. Epub 2024 Mar 12. Cancer. 2024. PMID: 38470379
406 results